8
Participants
Start Date
June 30, 2014
Primary Completion Date
November 30, 2015
Study Completion Date
November 30, 2015
BMS-936559
0.3 mg/kg, 1 mg/kg, 3 mg/kg, or 10 mg/kg of BMS-936559, depending on which cohort participants are enrolled in, administered as an intravenous (IV) infusion
Placebo for BMS-936559
Sodium chloride for injection 0.9%, USP, administered as an IV infusion
Chapel Hill CRS, Chapel Hill
Vanderbilt Therapeutics (VT) CRS, Nashville
Cincinnati Clinical Research Site, Cincinnati
University of Colorado Hospital CRS, Aurora
Washington University Therapeutics (WT) CRS, St Louis
National Institute of Allergy and Infectious Diseases (NIAID)
NIH